[ICO-1 monoclonal antibodies against the constant region of Ia-like (Dr) antigens].
Mouse monoclonal antibodies ICO-1 to constant part of Ia-Like (Dr) antigens were produced. Hybridoma continuously produced IgG3 antibodies during 22 passages in vivo, more than 7 months in vitro. Antibodies specifically bound to 29.1 +/- 2.3% of peripheral blood mononuclear cells of healthy people recognized the antigen on B lymphocytes and 44.2 +/- 3.4% of monocytes. This antigen was absent on granulocytes and T lymphocytes. Using monoclonal antibodies ICO-1 antigenically positive cells were detected in 40 patients with B-CLL, in 12 of 35 patients (34.3%) with chronic granulocytic leukemia at the stage of blastic crisis, in 43 of 65 patients (66.1%) with ALL, in 14 of 38 patients (36.8%) with lymphosarcoma and in 17 of 30 patients with acute myelomonocytic leukemia. The antibodies responded to surface antigens in the reaction of indirect surface immunofluorescence, complement-dependent cytotoxic reaction and radioimmune tests.
D000818:Animals; D005455:Fluorescent Antibody Technique; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006825:Hybridomas; D007525:Isoelectric Focusing; D007938:Leukemia / Q000276:immunology*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011379:Prognosis; D051381:Rats
D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II
Monoklonal'nye antitela IKO-1 protiv konstantnoĭ chasti Ia-podobnykh (Dr) antigenov.